Skip to main content

Animations

MJFF Publications

3531 - 3540 of 8823 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2023
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • Summary Details
    OPEN
    Title: Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
    Journal Name: Journal of Visualized Experiments
    Publisher: MyJove Corporation
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.3791/63313
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Unveiling the B cell receptor structure
    Journal Name: Science
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/science.add8065
    Citation Count: 12
  • Summary Details
    OPEN
    Title: Toward preventing Parkinson’s disease
    Journal Name: Science
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/science.add7162
    Citation Count: 15
  • Summary Details
    OPEN
    Title: Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mdc3.13751
    Citation Count: 10
  • Summary Details
    OPEN
    Title: GPNMB confers risk for Parkinson’s disease through interaction with α-synuclein
    Journal Name: Science
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/science.abk0637
    Citation Count: 141
  • Summary Details
    RESTRICTED
    Title: Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.abj2658
    Citation Count: 239
  • Summary Details
    OPEN
    Title: Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation
    Journal Name: ACS Chemical Neuroscience
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acschemneuro.2c00342
    Citation Count: 20
  • Summary Details
    OPEN
    Title: Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease
    Journal Name: Journal of Medicinal Chemistry
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acs.jmedchem.2c01605
    Citation Count: 21
  • Summary Details
    OPEN
    Title: Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study
    Journal Name: Diabetes Care
    Publisher: American Diabetes Association
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.2337/dc22-1705
    Citation Count: 127
  • Summary Details
    OPEN
    Title: Monitoring gait at home with radio waves in Parkinson’s disease: A marker of severity, progression, and medication response
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.adc9669
    Citation Count: 101
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.